Paasa Logo
Foghorn Therapeutics Inc. logo
FHTXNASDAQMarket closedOpens 9:30am ET

Foghorn Therapeutics Inc.

$3.52Last updated
+$0.02 (0.57%)Past day
Timezone

Foghorn Therapeutics Inc. (NASDAQ: FHTX) is trading at $3.52, about ₹338 at today's USD/INR rate, as of 28 Sep 2026, 4:00 PM ET, up 0.57% today. Indian residents can buy Foghorn Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:$3.49
Previous close:$3.50
Volume:336.94K

Today's low

$3.42

Today's high

$3.62

52 week low

$3.27

52 week high

$7.61

FHTX opened at $3.49, closed previously at $3.50, and has traded between $3.27 and $7.61 over the past 52 weeks.

About

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.

Country
US
CEO
Adrian H. Gottschalk
Exchange listed on
NASDAQ
Industry
Biotechnology
Base currency
USD
Full Time Employees
106
Sector
Healthcare
IPO date
23/10/2020

Key statistics

Avg. volume

324.47K

Market cap

$206.67M

P/E Ratio

-3.56

Price-to-sales ratio

5.63

Enterprise value

$181.70M

Free cash flow yield

-41.30%

Debt-to-equity ratio

-0.53

Return on equity

72.64%

ROIC

-44.00%

Beta

2.86

Dividend yield

0.00%

Last dividend

$0.00

Financial overview

Revenue

$30.91M

Earnings per share

-$1.18

Free cash flow

-$86.15M

Net profit margin

-175.78%

Gross margin

42.73%

EBITDA

-$70.95M

Revenue growth

36.75%

Similar securities

This is not an investment recommendation

How to buy Foghorn Therapeutics from India

Indian residents can buy Foghorn Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.

  3. Search for Foghorn Therapeutics and place an order

    Find Foghorn Therapeutics by name or by its ticker, FHTX, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Foghorn Therapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Foghorn Therapeutics position in USD and INR. Foghorn Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Foghorn Therapeutics from India

Trading and taxes when buying Foghorn Therapeutics from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneFoghorn Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
US estate tax
May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator

Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

FAQs

Can Indian residents buy Foghorn Therapeutics stock?

Yes. Foghorn Therapeutics (FHTX) has been listed on NASDAQ since 2020, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

How much does one Foghorn Therapeutics share cost in rupees?

One Foghorn Therapeutics share is $3.52 — about ₹338 at a USD/INR rate of 96.07 on 28 Sep 2026. Both the Foghorn Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Foghorn Therapeutics from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Can I buy whole shares of Foghorn Therapeutics?

Yes. One Foghorn Therapeutics share is $3.52, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Foghorn Therapeutics.

How are gains on Foghorn Therapeutics shares taxed in India?

The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Foghorn Therapeutics price. Paasa issues a capital-gains statement for your return.

Does Foghorn Therapeutics pay a dividend?

No. Foghorn Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Foghorn Therapeutics from India?

NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.

Is there estate or inheritance tax on Foghorn Therapeutics shares held from India?

US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.

Do I have to declare Foghorn Therapeutics shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Foghorn Therapeutics holding, its cost and its closing value.

How do I sell Foghorn Therapeutics and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.